Disintegrating Tablets For Parkinson’s Disease
Schwarz Pharma AG has received final approval from the FDA to market carbi-dopa-levodopa (Parcopa™) orally disintegrating tablets.
The drug’s unique formulation dissolves rapidly in the mouth, thereby providing patients suffering from Parkinson’s disease with improved access to their medication.
strattera medication
In comparison with their current tablets, patients preferred Parcopa™ for several reasons associated with the daily challenges of managing this complex disease. Unlike conventional carbidopa-levodopa, the RapiTab™ technology delivers the medication without the need for water.
